Quest Diagnostics Inc vs Invesco WilderHill Clean Energy ETF — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.23B), while Invesco WilderHill Clean Energy ETF trades at $34.96. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while Invesco WilderHill Clean Energy ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Invesco WilderHill Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| DGX | PBW | |
|---|---|---|
Market Cap | $26.23B | — |
Sector | Health | Sector/Thematic |
52-Week High | $238.50 | $46.99 |
52-Week Low | $173.49 | $24.14 |
Enterprise Value | $31.99B | — |
Dividend Yield | 1.45% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $238.35, down slightly by 0.06% today, but maintains a bullish technical trend with strong earnings momentum, having beaten EPS estimates in the last three quarters. Revenue grew to $11.04 billion in 2025, with net income reaching $992 million, and the company raised its 2026 outlook amid surging testing demand. Analyst consensus is a Buy with a $249.50 price target, though valuation multiples like a P/E of 25.3 suggest premium pricing.
The outlook for DGX is positive due to robust demand for diagnostic services, AI integration, and partnerships driving growth, but risks include margin pressure from lower-margin deals and high debt levels. Investors may find opportunity in sustained earnings beats and dividend payouts, yet should monitor competitive and cost pressures that could affect profitability.
PBW trades at $34.81, up 3.48% today, with a neutral technical signal and mixed moving averages. The clean energy ETF shows strength amid sector tailwinds from geopolitical tensions and data center demand, though it faces volatility from interest rate sensitivity. A dividend of $0.24 is scheduled for June 2026, but key valuation ratios like P/E and P/S are unavailable in the data.
The outlook hinges on clean energy adoption trends and Federal Reserve policy, with opportunities in global investment shifts but risks from rate cycles and oil price swings. Analyst sentiment is divided, reflecting the ETF's exposure to macroeconomic factors over company-specific fundamentals.
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →